Richard A. Heyman - 12 Feb 2026 Form 4 Insider Report for Enliven Therapeutics, Inc. (ELVN)

Role
Director
Signature
/s/ Ben Hohl, by power of attorney
Issuer symbol
ELVN
Transactions as of
12 Feb 2026
Net transactions value
$0
Form type
4
Filing time
17 Feb 2026, 20:00:10 UTC
Previous filing
22 Jan 2026
Next filing
19 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Heyman Richard A. Director C/O ENLIVEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, BOULDER /s/ Ben Hohl, by power of attorney 17 Feb 2026 0001584759

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELVN Stock Option (right to buy) Award $0 +19,234 $0.000000 19,234 12 Feb 2026 Common Stock 19,234 $27.16 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2026 annual meeting of the Issuer's stockholders or (ii) the date of the 2027 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director through the applicable vesting date.